PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, marking a substantial milestone in its growth trajectory. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
PlasmaGen Biosciences is a leading player in the plasma fractionation industry, operating one of India’s five plasma fractionation facilities near Bengaluru. The company’s state-of-the-art facility is equipped to manufacture a range of life-saving therapies, including immunoglobulins, albumin, and coagulation factors. These therapies are used to treat a variety of serious diseases, such as immunodeficiency disorders, bleeding disorders, and shock.
The funding round led by ViNS Bioproducts is a testament to the growing interest in India’s biotechnology sector, particularly in the plasma fractionation space. PlasmaGen’s commitment to delivering high-quality therapies has earned it a reputation as a trusted player in the industry. The company’s focus on innovation, quality, and customer satisfaction has enabled it to establish a strong presence in the Indian market and expand its reach globally.
With the fresh infusion of capital, PlasmaGen plans to further enhance its manufacturing capabilities, expand its product portfolio, and strengthen its research and development efforts. The company aims to increase its production capacity to meet the growing demand for plasma-derived therapies in India and internationally. Additionally, PlasmaGen intends to explore new markets and collaborate with global partners to accelerate its growth.
The investment by ViNS Bioproducts is a strategic move, given the company’s expertise in the biotechnology sector. ViNS Bioproducts has a strong track record of investing in innovative companies with high growth potential. The partnership between PlasmaGen and ViNS Bioproducts is expected to drive growth, innovation, and expansion in the plasma fractionation industry.
PlasmaGen’s existing investors, including Eight Roads, FIL Capital, and F-Prime, have also demonstrated their continued support for the company’s vision and growth plans. These investors have a deep understanding of the biotechnology sector and have backed several successful companies in the space. Their involvement has been instrumental in shaping PlasmaGen’s strategy and driving its expansion.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by government initiatives, increasing demand for innovative therapies, and investments from domestic and international players. The sector is expected to continue its upward trajectory, with the plasma fractionation industry playing a critical role in the development of life-saving therapies.
In conclusion, PlasmaGen Biosciences’ successful funding round and significant valuation milestone are a testament to the company’s commitment to delivering high-quality therapies and its vision for growth and expansion. With the support of its investors, including ViNS Bioproducts, Eight Roads, FIL Capital, and F-Prime, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived therapies and emerge as a leading player in the global biotechnology industry.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
